Immuron Ltd Files 6-K Report
Ticker: IMRN · Form: 6-K · Filed: Oct 2, 2025 · CIK: 1660046
| Field | Detail |
|---|---|
| Company | Immuron LTD (IMRN) |
| Form Type | 6-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, sec, foreign-private-issuer
TL;DR
Immuron Ltd filed a 6-K, check for updates on their announcements.
AI Summary
On October 2, 2025, Immuron Limited filed a Form 6-K, reporting on two public announcements made during October 2025. The company is a foreign private issuer and files annual reports under Form 20-F. The filing does not provide specific details on the content of the announcements or any financial figures.
Why It Matters
This filing indicates Immuron Limited is providing updates to the SEC, which could contain material information for investors regarding the company's operations or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain specific financial or operational disclosures that would immediately indicate high risk.
Key Players & Entities
- Immuron Limited (company) — Registrant
- 001-38104 (company) — Commission File Number
- October 2025 (date) — Reporting period for announcements
- Form 20-F (document) — Annual report filing type
- 62 Lygon Street, Carlton South, Victoria, 3053, Australia (address) — Principal executive office address
FAQ
What specific announcements were made by Immuron Limited in October 2025?
The filing states that two announcements were published but does not detail their content.
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that provides information which the company makes or is required to make public pursuant to the laws of its home country, or which it furnishes or is required to furnish to its security holders.
Does this filing contain financial results for Immuron Limited?
No, this Form 6-K filing does not contain specific financial results; it only reports that announcements were made.
What is Immuron Limited's primary business sector?
Immuron Limited is in the Pharmaceutical Preparations sector, SIC code 2834.
Where is Immuron Limited's principal executive office located?
Immuron Limited's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Filing Stats: 306 words · 1 min read · ~1 pages · Grade level 18.2 · Accepted 2025-10-01 20:59:19
Filing Documents
- ea0259861-6k_immuron.htm (6-K) — 12KB
- ea025986101ex99-1_immuron.htm (EX-99.1) — 21KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- ex99-1_002.jpg (GRAPHIC) — 7KB
- ex99-1_003.jpg (GRAPHIC) — 3KB
- 0001213900-25-094905.txt ( ) — 55KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published two announcements (the “Public Notices”) to the Australian Securities Exchange on October 2, 2025 titled: - Letter to shareholders A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Letter to shareholders 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: October 2, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3